medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Number 2

<< Back Next >>

Ann Hepatol 2002; 1 (2)

Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid

Méndez-Sánchez N, Panduro A, Murguía D, Rincón AR, Uribe M

Language: English
References: 40
Page: 85-89
PDF size: 208.51 Kb.


Text Extraction

Objective: It has been suggested that apo A-I can inhibit cholesterol crystal nucleation in vitro, and ursodeoxycholic acid (UDCA) is a safe and effective treatment for selected patients with cholesterol gallstones the aim of this study was to investigate the effect of UDCA on the steady-state levels (SSL) of apo A-I mRNA in the liver, as well as serum apo A-I, in patients with cholesterol gallstones.
Design: Twenty Mexican patients with symptomatic radiolucent gallstones were randomized and assigned in a double blind fashion to groups that were administered either UDCA (4 mg/kg per day) or placebo for 10 to 15 days before cholecystectomy.
Methods: Apo A- I mRNA levels in liver and gallbladder tissues were determined by northern blot and serum levels of apo A- I by turbidimetric method.
Results: Apo A- I mRNA levels were higher in nine of the 10 patients who received UDCA and in comparison to those to the placebo group. In the gallbladder apo A- I mRNA levels were undetected. Serum levels (mg/dL) of apo A- I were similar in both UDCA and placebo groups after treatment (111.7 ± 29.8 vs 115.6 ± 25.4).
Conclusions: The results of this study shown that apo A- I mRNA gene express at the mRNA level in the liver but not in the gallbladder of patients with cholesterol gallstones treated with UDCA.


REFERENCES

  1. Silver DL, Jiang JC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of Apo A-I and Apo A-II, and decreased Apo A-I mRNA in ob/ob mice. J Biol Chem 1999; 274: 4140-4146.

  2. Mooradian AD, Wong NC, Shah GN. Age-related changes in the responsiveness of apolipoprotein A1 to thyroid hormone. Am J Physiol 1996; 271: R1602-7.

  3. Zaiou M, Azrolan N, Hayek T, Wang H, Wu L, Haghpassand M, et al. The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1. J Clin Invest 1998; 101: 1699-1707.

  4. Azrolan N, Odaka H, Breslow JL, Fisher EA. Dietary fat elevates hepatic apo A-I production by increasing the fraction of apolipoprotein A-I mRNA in the translating pool. J Biol Chem 1995; 270; 19833-19838.

  5. Kibe A, Holzbach RT, LaRusso NF, Mao SJT. Inhibition of cholesterol crystal formation by apolipoproteins in supersaturated mode bile. Science 1984; 255: 514-16.

  6. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 1994; 204: 1-15.

  7. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000; 32(Suppl 1): 129-40.

  8. May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. Aliment Pharmacol Ther 1993; 7: 139-48.

  9. Petroni ML, Jazrawi RP, Pazzi P, Lanzini A, Zuin M, Pigozzi MG, et al. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British–Italian Gallstone Study Group. Aliment Pharmacol Ther 2001; 15: 123-8.

  10. Jungst D, Brenner G, Pratschke E, Paumgartner G. Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones. J Hepatol 1989; 8: 1-6.

  11. Tazuma S, Sasaki H, Mizuno, Sawaga H, Hashiba S, Horiuchi Y, et al. Effect of ursodeoxycholic acid administration on nucleation time in human gallbladder bile. Gastroenterology 1989; 97: 173-8.

  12. Sutor DJ. X-ray diffraction studies of composition of gallstones from English and Australian patients. Gut 1969; 10: 681-3.

  13. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Annal Biochem 1987; 162: 156-9.

  14. Panduro A, Shalaby F, Weiner F, Biempieca L, Zern M, Shafritz DA. Transcriptional switch from albumin to alpha-fetoprotein and changes in transcription of other genes during CC14 induced liver regeneration. Biochemistry 1986; 25: 1414-20.

  15. Panduro A, Lin-Lee Y, Chan L, Shafritz DA. Transcriptional and post-transcriptional regulation of apolipoprotein E, A-I and A-II gene expression in normal rat liver and during several pathophysiologic states. Biochemistry 1990; 29: 8130-35.

  16. Summers J. Physical map of polyoma viral DNA fragments produced by cleavage with restriction enzyme from Haemophilus aegyptius endonuclease R, Hae II. J Virol 1975; 15: 946-953.

  17. Maldonado V, Chan L, Meléndez J, Rincón AR, Zhu Hui-Hia, Panduro A. Regulation of apo B mRNA expression in liver and intestine during liver regeneration induced by CC14. Biochim Biophys Acta 1994; 1211: 1-6.

  18. Siedel J, Schlumberger H, Klose S, Ziegenhorn J, Wahlefeld AW. Improved reagent for the enzymatic determination of serum cholesterol. J Clin Chem 1981; 19: 838-9.

  19. Lehnus G, Smith L. Automated procedure for kinetic measurement of total triglyceride (as glycerol) in serum with the Gilford system 3500. Clin Chem 1978; 24: 27-31.

  20. Burnstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-595.

  21. Bronzert T, Brewer HB. New micromethod for measuring cholesterol in plasma lipoproteins fractions. Clin Chem 1977; 23: 2089-1098.

  22. Weiswell P, Schawardt P. Hyperlipoproteinemia: the apolipoprotein determination. Med Lab 1985; 13: 10-16.

  23. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill; 1971: 149-160.

  24. Panduro A, Castrillon L, Gonzalez L, Shafritz DA. Regulation of hepatic and non-hepatic apolipoprotein A-I and E gene expression during liver regeneration. Biochim Biophys Acta 1993; 1167: 37-42.

  25. Swell RB, Mao SJ, Kawamoto T, LaRusso NF. Apolipoproteins of high, low, and very low density lipoproteins in human bile. J Lipid Res 1983; 24: 391-401.

  26. Kawamoto T, Mao SJT, LaRusso NF: Biliary excretion of apolipoprotein B by the isolated perfused rat liver. Gastroenterology 1987; 92: 1236-1242.

  27. Poynard T, Lonjon I, Mathurin P, Abella A, Musset D, Bedossa P, et al. Prevalence of cholelithiasis according to alcoholic liver disease: a possible role of apolipoproteins AI and AII. Alcohol Clin Exp Res 1995; 19: 75-80.

  28. Mathurin P, Vidaud D, Vidaud M, Bedossa P, Paradis V, Ratziu V, et al. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology 1996; 23: 44-51.

  29. Baranda J, Ministro P, Amaro P, Rosa A, Pimenta I, Donato A, et al. Apolipoprotein A1 and biliary lithiasis in hepatic cirrhosis. Acta Med Port 1996; 9: 203-6.

  30. Cahalane MJ, Neubrand MW, Carey MC. Physical-chemical pathogenesis of pigment gallstones. Semin Liver Dis 1988; 8: 317-328.

  31. Ohta T, Nagakawa T, Takeda T, Fonseca L, Kanno M, Mori K, et al. Histological evaluation of the intrahepatic biliary tree in intrahepatic cholesterol stones, including immunohistochemical staining against apolipoprotein A-1. Hepatology 1993; 17: 531-7.

  32. Pattinson NR, Upton P, Ellingsen PJ, Chapman BA. Apolipoprotein localization in the human bile duct and gallbladder. Pathology 1990; 22: 55-60.

  33. Secknus R, Yamashita G, Ginanni Corradini S, Chernosky A, Williams C, et al. Purification and characterization of a novel human 15 kd cholesterol crystallization inhibitor protein in bile. J Lab Clin Med 1996; 127: 169-78.

  34. Secknus R, Darby GH, Chernosky A, Juvonen T, Moore EW, Holzbach RT. Apolipoprotein A-I in bile inhibits cholesterol crystallization and modifies transcellular lipid transfer through cultured human gallbladder epithelial cells. J Gastroenterol Hepatol 1999; 14: 446-56.

  35. Ginanni Corradini S, Elisei W, Giovannelli L, Ripani C, Della Guardia P, Corsi A, et al. Impaired human gallbladder lipid absorption in cholesterol gallstone disease and its effect on cholesterol solubility in bile. Gastroenterology 2000; 118: 912-920.

  36. Pérez Barriocanal F, Marin JJ, Dumont M, Erlinger S. Influence of backward perfusion on ursodeoxycholate-induced choleresis in isolated in situ rat liver. J Hepatol 1990; 11: 165-71.

  37. Berr F, Jaeger H, Walli A, Bittherle TH, Wilcox H. Biliary secretion of phospholipids and apolipoprotein A-1: evidence for intracellular supply of phospholipids by a non-vesicular transport route. (Abstract). Hepatology 1993; 18: 179.

  38. Van Erpecum KJ, Portincasa P, Eckhardt E, Go PM, VanBerge-Henegouwen GP, Groen AK. Ursodeoxycholic acid reduces protein levels and nucleation-promoting activity in human gallbladder bile. Gastroenterology 1996; 110: 1225-37.

  39. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994; 14: 707-20.

  40. Fidge N, Nestel P, Ishikawa T, Reardon M, Billington T. Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism 1980; 29: 643-53.




2020     |     www.medigraphic.com